Earnings
Tango Therapeutics Swings To $68.4 Million Loss As Cancer Development Costs Climb
Collaboration revenue fell to zero, while Tango prepares a late-stage pancreatic-cancer study and January data releases.
Tango Therapeutics (TNGX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Collaboration revenue fell to zero, while Tango prepares a late-stage pancreatic-cancer study and January data releases.
SEC Filings
The biotech plans a front-line Phase 3 trial in the first half of 2027 while narrowing its research to PRMT5 drugs.